Neurocrine Biosciences, Inc.(NBIX) Stock Research - Grey Stern Research

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis

$120.46 (0.51%)

NBIX Financial Performance


Use the table below to view Neurocrine Biosciences, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $119.85 -
52 Week Low $103.63 -
52 Week High $157.98 -
Market Cap $12.1 Billion 1/14
Gross Margin 97% 2/14
Profit Margin 11% 7/14
EBITDA margin 26% 7/14
Q2 - 2024 Revenue $590.2 Million 1/14
Q2 - 2024 Earnings $65.0 Million 2/14
Q2 - 2024 Free Cash Flow $53.0 Million 5/14
Trailing 4 Quarters Revenue $2.1 Billion 1/14
Trailing 4 Quarters Earnings $339.2 Million 1/14
Quarterly Earnings Growth -32% 12/14
Annual Earnings Growth 353% 2/14
Quarterly Revenue Growth 30% 4/14
Annual Revenue Growth 24% 3/14
Cash On Hand $139.7 Million 7/14
Short Term Debt $35.4 Million 2/14
Long Term Debt $256.2 Million 8/14

Neurocrine Biosciences, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Neurocrine Biosciences, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 35.68 4/14
PS 5.71 5/14
PB 4.82 5/14
PC 86.63 2/14
Liabilities to Equity 0.32 12/14
ROA 0.10 4/14
ROE 0.14 4/14
Current Ratio 4.15 2/14
Quick Ratio 1.31 4/14
Long Term Debt to Equity 0.10 9/14
Debt to Equity 0.12 9/14
Burn Rate -3.04 8/14
Cash to Cap 0.01 13/14
CCR 0.82 9/14
EV to EBITDA 78.96 2/14
EV to Revenue 5.78 5/14

Company Details

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

CEO: Dr. Kevin Gorman

Website: https://www.neurocrine.com

Address: 12780 El Camino Real San Diego, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Drug Manufacturers—Specialty & Generic

Neurocrine Biosciences, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Neurocrine Biosciences, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Prestige Consumer Healthcare Inc. PBH $3.7 Billion
Dynavax Technologies Corporation DVAX $1.5 Billion
Pacira BioSciences, Inc. PCRX $677.6 Million
Ironwood Pharmaceuticals, Inc. IRWD $720.4 Million
Supernus Pharmaceuticals, Inc. SUPN $1.8 Billion
Collegium Pharmaceutical, Inc. COLL $1.3 Billion
Avadel Pharmaceuticals plc AVDL $1.3 Billion
Eagle Pharmaceuticals, Inc. EGRX $55.5 Million
Alkermes plc ALKS $4.7 Billion
Intra-Cellular Therapies, Inc. ITCI $8.1 Billion
ANI Pharmaceuticals, Inc. ANIP $1.3 Billion
Amphastar Pharmaceuticals, Inc. AMPH $2.4 Billion
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
NBIX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 590.2 Million $65.0 Million
Q1 2024 $ 515.3 Million $43.4 Million
Q4 2023 $ 515.2 Million $147.7 Million
Q3 2023 $ 498.8 Million $83.1 Million
Q2 2023 $ 452.7 Million $95.5 Million
Q1 2023 $ 420.4 Million -$76.6 Million
Q4 2022 $ 412.0 Million $89.0 Million
Q3 2022 $ 387.9 Million $68.5 Million

View All

NBIX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $139.7 Million $3.3 Billion $291.6 Million $2.5 Billion
Q1 2024 $396.3 Million $3.5 Billion $546.9 Million $2.4 Billion
Q4 2023 $251.1 Million $3.3 Billion $428.4 Million $2.2 Billion
Q3 2023 $293.7 Million $2.8 Billion $255.8 Million $2.0 Billion
Q2 2023 $160.2 Million $2.6 Billion $258.8 Million $1.9 Billion
Q1 2023 $90.4 Million $2.4 Billion $259.9 Million $1.7 Billion
Q4 2022 $262.9 Million $2.4 Billion $262.9 Million $1.7 Billion
Q3 2022 $212.2 Million $2.1 Billion $265.8 Million $1.5 Billion

View All

NBIX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $53.0 Million -$11.6 Million -$256.6 Million
Q1 2024 $119.1 Million -$11.2 Million $145.2 Million
Q4 2023 $118.1 Million -$5.4 Million -$42.6 Million
Q3 2023 $204.4 Million -$7.6 Million $133.5 Million
Q2 2023 $0 $0 $0
Q1 2023 -$133.7 Million -$8.5 Million -$159.1 Million
Q4 2022 $141.2 Million -$1.8 Million $50.7 Million
Q3 2022 $100.5 Million $1.7 Million $48.9 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions